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Introduction {#sec005}
============

Uveal melanoma (UM) is the most common primary intraocular malignancy in the adult, representing 5--6% of all melanomas (annual incidence in Europe approximately 5:1000000), and is associated with age and, light skin and blue pigmented eyes\[[@pone.0120181.ref001],[@pone.0120181.ref002]\]. Although local control is achieved in most cases, approximately 50% of patients will develop systemic disease \[[@pone.0120181.ref001]\]. Although the liver is the most common site of metastatic disease, UM can metastasize to any including the lungs, bones, soft tissues, gastrointestinal tract, ovaries, kidneys and central nervous system (CNS)\[[@pone.0120181.ref002], [@pone.0120181.ref003]\]. The reported median life expectancy of patients affected by metastatic UM (mUM) ranges from 3.6 to 15 months \[[@pone.0120181.ref004]\]. Site; number and diameter of metastases; percentage of liver substitution, presence of symptoms; alteration of liver function tests, especially alkaline phosphatase (ALP) and lactic dehydrogenase (LDH); older age; male sex; and a shorter metastasis-free interval have been associated with a poorer prognosis \[[@pone.0120181.ref002], [@pone.0120181.ref005]--[@pone.0120181.ref010]\]. Due to several known and unknown factors, as for mucosal, acral and skin melanomas, UM is a poor responder to antiblastic chemotherapy and radiotherapy\[[@pone.0120181.ref011]\]. Moreover, UM cannot benefit from target therapy tailored for cutaneous melanoma, as BRAF inhibitors, because of the absence of the target mutation\[[@pone.0120181.ref012]\] and, for reasons yet to be explored, response to new immunotherapies is poorer than for cutaneous melanoma\[[@pone.0120181.ref013]\]. Treatments for mUM can be divided into liver directed treatments; such as surgical resection \[[@pone.0120181.ref009]\], ablation \[[@pone.0120181.ref014]\], radiation \[[@pone.0120181.ref014]\], hepatic arterial chemoinfusion \[[@pone.0120181.ref015], [@pone.0120181.ref016]\], immunoembolization \[[@pone.0120181.ref017]\], transarterial chemoembolization \[[@pone.0120181.ref018]\], radioembolization \[[@pone.0120181.ref019]\], isolated or percutaneous hepatic perfusion \[[@pone.0120181.ref020], [@pone.0120181.ref021]\]; and into systemic treatments; such as chemotherapy (antineoplastic drugs used alone or in combinations \[[@pone.0120181.ref022]\]), immunotherapy (interferon \[[@pone.0120181.ref023]\], interleukin-2 \[[@pone.0120181.ref024]\], and, more recently, ipilimumab\[[@pone.0120181.ref013]\]), anti-angiogenetic drugs \[[@pone.0120181.ref025], [@pone.0120181.ref026]\], and targeted agents such as MEK inhibitors \[[@pone.0120181.ref027], [@pone.0120181.ref028]\]. Despite the efforts to improve mUM outcomes, prognosis remains poor and clinicians lack a standard prognostic tool. The study objective was to identify the independent prognostic factors for mUM in order to formulate a reproducible prognostic algorithm, that could be easily enough to be integrated into clinical practice.

Patients and Methods {#sec006}
====================

Patients and Therapies {#sec007}
----------------------

The prospective melanoma databases at the Melanoma Oncology Unit of the Veneto Oncology Institute (IOV) and at Mayo Clinic, Rochester (MC) were queried under institutional review board approval for mUM. IOV patients (N = 152) were diagnosed and treated between September 1990 to October 2013, MC patients (N = 102) were diagnosed and treated between January 2000 and August 2013. The majority of patients from IOV (72.4%) and MC (84.3%) were treated with Iodine-125-brachitherapy for their primary melanoma; the remaining patients received enucleation, with the exception of those in whom treatment of their primary melanoma was futile as they presented with stage IV disease. Material for fluorescent in-situ hybridization analysis (FISH) of the primary tumor was obtained with a 25-gauge trans-scleral fine needle aspiration biopsy. FISH was used to evaluate the cell karyotype and alterations of chromosomes 1, 3, 6, 8 and 10. Procedure and testing was performed using previously published methods \[[@pone.0120181.ref029]--[@pone.0120181.ref031]\]. Metastases were discovered at initial staging (6 IOV patients and 3 MC patients) or during follow-up via ultrasound tomography or computed tomography (CT). Diagnosis was confirmed via core biopsy or fine needle aspiration cytology. Staging was completed with CT or magnetic resonance (MR) when not previously performed. Therapy was chosen according to the localization of metastases and the availability of clinical trials.

Gender, age; date, size and characteristics of UM; date and site of metastases; date, type and outcome of therapies; date of last follow up or death and cause of death were collected from patient records. Date and cause of death were collected from local registry offices, and telephone interviewing of family or from general practitioners for patients lost to follow up. Levels of LDH, alkaline phosphatase (ALP), ϒ-glutamyltranspeptidase (ϒGT) and transaminases were recorded at diagnosis of metastatic disease and were computed as proportion of the respective upper normal value. The site and extent of metastases at baseline were quantified with CT (IOV cohort and most MC patients) or MR (a minority of MC patients). Liver metastasis volumes were calculated with three-dimensional reconstruction by helical CT or MR of the liver and registered as the percentage of liver substitution; we retrospectively reviewed CT images of the IOV cohort with Syngo CT Oncology software (version 2009E, Siemens, Germany) for confirmation and to assess the maximum diameter and the number of liver metastases. It was decided not to include this information as the percentage of liver substitution was considered the best indicator of effective volume of hepatic disease. Moreover, some patients had many small metastases, making analysis of diameter and number very complex.

The study was approved by the Institutional Review Boards of Veneto Region Oncology Research Institute, Padova, and Mayo Clinic, Rochester. All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. All patients gave written informed consent to the use of their records for research purposes.

Statistical Analysis {#sec008}
--------------------

Patient features and clinical characteristics were analyzed using the Mann-Whitney two-tailed U test (continuous variables) and χ^2^ test (categorical variables). Disease-free interval (DFI) was defined as the time from initial UM diagnosis to first noted metastasis. Overall survival (OS) was defined as the time from diagnosis of first metastasis to the date of death or last follow-up. OS was estimated using the Kaplan-Meier method and survival between cohorts was analyzed using the log-rank test. Cox proportional hazards regression was used on the IOV dataset to examine the association between potential prognostic variables and survival. Age at diagnosis of UM was not tested because it collimated with the other temporal covariates. Schoenfeld residual-based methodology was used to verify the proportional hazard assumption of the Cox model. The Wald test was used to assess the significance of each variable included within the full model. Only variables with *p* values ≤.05 were maintained in the final model after fast-backward variable selection. The performance of the model was measured in terms of calibration (with the area under the receiver operating characteristic curve) and discrimination (Harrell's C-index). Shrinkage slope after 100 bootstrap replications was calculated as a measure of overfitting. The prognostic model was externally validated using the MC dataset. The prognostic nomogram was tailored using the final regression model with the total number of points derived by specifying values used to calculate the expected survival probabilities at 6, 12 and 24 months. Missing values were estimated with multiple imputation using additive regression, bootstrapping, and predictive matching. The estimation procedure was corrected using 20 multiple imputations. Patients whose death was unrelated to UM progression were censored at last follow-up (2 IOV and 0 MC patients). *P* values were calculated using two-tailored testing, and confidence intervals (CI) are reported at the 95% level. Statistical analysis was performed using R 2.15.2 (survival, Hmisc and rms libraries).

Results {#sec009}
=======

Patient Characteristics {#sec010}
-----------------------

Descriptive statistics are summarized in [Table 1](#pone.0120181.t001){ref-type="table"}.

10.1371/journal.pone.0120181.t001

###### IOV and MC patient characteristic at diagnosis of stage IV disease.

![](pone.0120181.t001){#pone.0120181.t001g}

  Patients characteristics          IOV (*N* = 152)                       MC(*N* = 102)                       
  --------------------------------- ----------------- ------------------- --------------- ------------------- ------------
  Sex                                                                                                         .271
  Female                            73 (48.1)                             41 (40.2)                           
  Male                              79 (51.9)                             61 (59.8)                           
  Age of primary UM (years)                           60.9 (25.3--82.5)                   59.0 (28.0--92.0)   .352
  Age of 1^st^ metastasis (years)                     63.6 (34.3--89.4)                   61.5 (30.0--92.0)   .262
  DFI (months)                                        25.2 (0--339.2)                     24.1 (0.1--140.8)   .703
  Number of organs involved                                                                                   .803
  1                                 108 (71.1)                            72 (70.6)                           
  2                                 32 (21.0)                             19 (18.6)                           
  3≤                                12 (7.9)                              11 (10.8)                           
  Liver metastasis                                                                                            **\<.001**
  No                                9 (5.9)                               14 (13.7)                           
  Yes                               143 (94.0)                            88 (86.3)                           
  \<20%                             63 (41.4)                             68 (66.7)                           
  20≤50%                            48 (31.5)                             16 (15.7)                           
  50%≤                              19 (12.5)                             4 (3.9)                             
    *Missing data*                  14 (9.2)                              0                                   
  LDH (x UNL)                                         0.8 (0.3--15.6)                     0.9 (0.5--10.4)     **.005**
  ϒGT (x UNL)                                         1.1 (0.1--27.9)                     0.9 (0.4--25.3)     .761
  AST (x UNL)                                         0.7 (0.2--11.8)                     0.6 (0.3--10.4)     .901
  ALT (x UNL)                                         0.6 (0.2--7.6)                      0.9 (0.3--3.1)      .109
  PS                                                                                                          **.008**
  0                                 93 (61.1)                             61 (59.8)                           
  1                                 46 (30.3)                             9 (8.8)                             
  2                                 9 (5.9)                               2 (1.9)                             
  3                                 4 (2.6)                               1 (0.9)                             
  *Missing data*                    0                                     29 (28.4)                           
  1^st^ line treatment of mUM                                                                                 **\<.001**
  No treatment                      21 (13.8)                             0                                   
  Any treatment                     131 (86.2)                            102 (100)                           
   Systemic therapy alone           56 (54.9)                             74 (72.5)                           
  Locoregional therapy alone        17 (16.7)                             17 (16.7)                           
  Locoregional + systemic therapy   68 (44.7)                             5 (4.9)                             
  *Missing data*                    0                                     9 (8.8)                             

IOV = Veneto Oncology Research Institute,

MC = Mayo Clinic,

PS = Performance Status (according to World Health Organization classification),

(x UNL) = multiples of the upper normal limit.

Significant differences in the clinical characteristics between the two cohorts were noted in the percentage of liver substitution (MC patients had a lower frequency of hepatic metastases, and a lower percentage of liver substitution) performance status (PS) (MC cohort had lower frequency of patients with worse PS) and median values of LDH (IOV cohort had a lower median value).

Out of the 152 patients in IOV series, 131 received at least 1 line of therapy within 2 months from diagnosis of stage IV disease while 21 patients did not receive any treatment due to poor PS (4 had World Health Organization PS 3) or patient preference. All patients from MC received treatment for mUM with a higher percentage receiving systemic therapies over locoregional or combined approaches (locoregional plus systemic).

After a median follow-up of 11.4 months (0.4--89.9), 33 (22%) out of 152 patients from IOV were alive and 11 (7.3%) were lost to follow-up. Among the 108 patients from IOV who were deceased at the time of the analysis, 107 (98.0%) died of liver failure due to disease progression, and one patient treated by IHP with melphalan died of acute liver failure 2 days after the procedure. The median follow-up of the 70 (68.6%) MC patients alive or lost to follow-up at the time of the analysis was 14.9 months (1.0--55.8), all deaths were due to disease progression.

Survival and Prognostic Nomogram {#sec011}
--------------------------------

The estimated median OS was 17.2 months (range 1.2--86.4) and 19.7 months (range 12.4--23.4) in the IOV and MC series, respectively. Twelve and 24-months survival was 63.4% and 34.5% for IOV and 61.7% and 35.6% for MC patients, respectively ([Fig. 1](#pone.0120181.g001){ref-type="fig"}). The survival analysis demonstrated that the difference between the two cohorts was not significant (*P* = .271).The following covariates were tested in a multivariate Cox regression model: sex, size and characteristics of primary UM, age at diagnosis of mUM, DFI, hepatic enzyme levels at diagnosis of mUM (LDH, ALP, ϒGT, transaminases), site and number of metastases, percentage of liver replacement and first line treatment. We observed that locoregional therapy was associated with a trend for longer survival \[[@pone.0120181.ref032], [@pone.0120181.ref033]\], although this was not statistically significant in the multivariate model. Clinical and histopathological characteristics of primary melanoma did not correlate with survival. A trend for shorter DFI in patients with worse primary melanoma characteristics, i.e. stage (*P =* .060), ciliary body involvement (*P =* .058) and epitheloid (*P* = .069) or mixed histology (*P* = 0.57) was noted, however not statistically significant. We observed enrichment for strongly pigmented and genomically aberrant cases. [S1 table](#pone.0120181.s003){ref-type="supplementary-material"} shows the correlation with survival for primary melanoma characteristics and their influence on OS at multivariate analysis. The significant covariates of the final model are showed in [Table 2](#pone.0120181.t002){ref-type="table"} while the nomogram for the predictive model is reported in [Fig. 2](#pone.0120181.g002){ref-type="fig"}. Increasing liver substitution (HR 1.6), serum LDH (HR 1.6) and PS (HR of 1.5 and 4.6 for PS 1 and 2--3, respectively) were associated with worse OS. Longer DFI was associated with better prognosis (HR 0.9). The effect of each predictor on survival is represented in [S1 Fig](#pone.0120181.s001){ref-type="supplementary-material"}.

![Overall survival of IOV and MC patients after diagnosis of first metastasis.\
No statistical difference was noted between the two survival curves (*P* = .271). Of note, both curves show a slope flatting after 20 months. Dotted lines refer to the 95% CI.](pone.0120181.g001){#pone.0120181.g001}

10.1371/journal.pone.0120181.t002

###### Predictive factors used in the final prognostic model.

![](pone.0120181.t002){#pone.0120181.t002g}

  Prognostic factor                Median value (range)   *N* of patients (%)   HR                                          *P*
  -------------------------------- ---------------------- --------------------- ------------------------------------------- ------------
  PS                                                                                                                        **\<.001**
  0 as baseline with HR = 1                               93 (61.1)             1                                           
  1                                \-                     46 (30.3)             1.5                                         
  2--3                             \-                     13 (8.5)              4.5                                         
  LDH (x UNL)                      0.8 (0.3--15.6)        \-                    1.6[^a^](#t002fn002){ref-type="table-fn"}   **.014**
  Liver substitution (%)           20 (0--80)             \-                    1.6[^a^](#t002fn002){ref-type="table-fn"}   **\<.001**
  Disease-free-interval (months)   25.2 (0--339.2)        \-                    0.9[^a^](#t002fn002){ref-type="table-fn"}   **\<.001**

PS = Performance Status (according to World Health Organization classification),

^a^ no linear relation.

![Nomogram of the final prognostic model.\
The sum of the prognostic factor points corresponds to the survival probability at 6, 12 and 24 months.](pone.0120181.g002){#pone.0120181.g002}

Although number of organs involved by metastatic disease and type of therapy received (locoregional, systemic or combined) showed some association with prognosis, this was not significant. No association with survival was noted for sex, liver function tests other than LDH and age of metastasis. Remodeling the nomogram to include molecular alterations did not improve its performance. The calibration accuracy was confirmed by the receiver operating characteristic curves shown in [Fig. 3](#pone.0120181.g003){ref-type="fig"}. The absence of systematic bias is confirmed by the closeness of the receiver operating characteristic curves; rough shrinkage was 0.9. The nomogram was validated with the external dataset of MC patients by assessing the reliability, as reported in [Table 3](#pone.0120181.t003){ref-type="table"}. The concordance probability was 0.75 (SE. 006) in the development dataset, and 0.80 (SE. 009) in the external validation. [S2 table](#pone.0120181.s004){ref-type="supplementary-material"} shows the Proportional Hazard Assumption confirmation of the final model. [S2 Fig](#pone.0120181.s002){ref-type="supplementary-material"}. shows an example of the nomogram use.

![Receiver operating characteristic curves of the calibration.\
Estimate of calibration accuracy was performed using adaptive spline regression. The line adjacent the ideal line corresponds to the apparent predictive accuracy. The blue line corresponds to corrected estimates.](pone.0120181.g003){#pone.0120181.g003}

10.1371/journal.pone.0120181.t003

###### External validation of the nomogram.

![](pone.0120181.t003){#pone.0120181.t003g}

  Nomogam   External validation                        
  --------- --------------------- ------ ------ ------ ------
  0.75      0.50                  .006   0.80   0.60   .009

SE = Standard Error.

Discussion {#sec012}
==========

We developed a nomogram that reliably stratifies prognosis for patients with mUM. This nomogram may allow oncologists treating patients with mUM to tailor treatments, allowing for better allocation of resources. Currently, surgeons and oncologists treating patients with mUM lack both a validated system to predict the patient prognosis and reliable decision making tools that may allow for the identification of patients who may actually be harmed by treatment of their metastatic disease. Although this is not as large of a concern in cancers that carry a relative good prognosis and have multiple treatment options with proven clinical benefit, it is a crucial determinant of clinical care for very rare tumors with no established standard treatment and potentially toxic therapies \[[@pone.0120181.ref028]\].

The two largest previously published series of patients with mUM did evaluate for prognostic factors \[[@pone.0120181.ref003], [@pone.0120181.ref034]\]. Other studies have tried to identify prognostic factors for patients with mUM, however these analyses were based on small series. Moreover, these works took into account only a limited number of putative prognostic factors \[[@pone.0120181.ref003], [@pone.0120181.ref005]--[@pone.0120181.ref010], [@pone.0120181.ref035], [@pone.0120181.ref036]\]. Of these studies, Eskelin *et*. *al* \[[@pone.0120181.ref006]\] constructed a prognostic model with PS, dimensions of liver metastasis, ALP levels (as substitute of LDH) and time on treatment using a multivariate analysis in 54 patients. Kodjikian *et al*. found that ciliary body involvement and more than 10 metastases conferred a worse prognosis by analyzing primary melanoma characteristics, age and the number of liver metastasis before surgery in 63 patients using a multivariate Cox regression. Finally, Rietschel *et al*. \[[@pone.0120181.ref010]\], showed that lung/soft tissue metastases, long DFI, locoregional treatments, female sex and younger age all conferred better prognosis, using a multivariate analysis on 119 patients. Unfortunately, none of these studies considered all of the previously identified prognostic factors and compared them in a multivariate analysis, nor did they adopt any calibration or validation strategy. These previous experiences testify to the difficulty faced when studying the prognostic factors for UM; the rarity of this disease makes the collection of a large, comprehensive series of all prognostic factors complex, with wide variations in diagnostic and treatment modalities over the time of observation. However, with the availability of new regional therapies and targeted drugs, a simple and validated model for patient risk stratification is needed. A reliable tool to evaluate the prognosis could aid clinicians in selecting the candidates for invasive or potentially toxic treatments, which should be reserved for patients with longer life expectancy. With the collaboration of two independent groups, enough data were collected to perform a reliable validation of a prognostic model, with modalities and sample sizes comparable to currently accepted nomograms for rare tumors\[[@pone.0120181.ref036]\].

Both clinico-pathological and modern molecular prognostic factors have been identified for primary uveal melanoma and are predictors of metastases. However, their usefulness in the metastatic setting has yet to be evaluated. Additionally, the modern molecular procedures, that have been demonstrated to be superior to clinic-pathological characteristics\[[@pone.0120181.ref037]\], are currently limited to experimental studies. Primary melanoma features, included ciliary body involvement, did not impact on survival in our series. However, we observed a trend for shortest DFI associated to worse primary melanoma characteristics, and this is consistent with the hypothesis that DFI is influenced by the biological aggressiveness of the tumor (reflected by primary melanoma characteristics), but also the result of the interaction of several concurrent variables (such as biological determinants of tumor and immunological equilibrium). We analyzed whether the addition of molecular alterations could improve the performance of the nomogram, however no statistically significant trends with these alterations were noted. One reason for this could be that these alterations have been associated with the development of metastatic disease for patients with mUM, while this study looked at the prognosis of patients who have already developed metastatic disease. The genomic (mainly chromosome 3, 6 and 8 aberrations \[[@pone.0120181.ref038], [@pone.0120181.ref039]\]) and genetic (for example the two gene-expression profiles identified by Onken *et al*. \[[@pone.0120181.ref040]\]) abnormalities are predictors of distant recurrence after UM primary diagnosis, then other biological factors, yet to be studied, may determine the aggressiveness of metastases when the disease has spread. We encourage future studies to explore the potential genomic and genetic alterations that may influence the prognosis of patients with mUM. Our experience suggests that large, collaborative studies are needed to obtain an adequate sample size to study potential molecular predictors of survival or new therapeutic options, given the rarity of the disease. Melanin is described as one of the potential causes for melanoma refractoriness to treatments\[[@pone.0120181.ref041]--[@pone.0120181.ref044]\]. There are no extensive data in the literature on the pattern of pigmentation and its prognostic importance in this rare subtype of melanoma. In our series all cases presented strong pigmentation. These data, although insufficient to assert conclusions, are hypothesis generating for further studies focused on mUM, also in the prospective to find the reasons of mUM poorer response to immunotherapies compared to its skin counterpart\[[@pone.0120181.ref013]\].

In both of our independent series, the survival is longer than other studies; however, similar survival times have been reported by Rietschel *et al*. \[[@pone.0120181.ref010]\] and Kodjikian *et al*. \[[@pone.0120181.ref045]\]. It is often not possible to extrapolate the time from the onset of stage IV disease and to that of the initiation of therapy from clinical trials. Additionally, most of the variables we studied were only partially included in other works, making it difficult to compare the OS and clinical predictors of our study with those that have been previously reported. Possible explanations for the differences in survival could include referral bias as both centers included in this study are large referral centers and lead time bias, as we noted shorter DFIs (25.2 and 24.1 months for the IOV and MC dataset, respectively) than those previously reported (30 months in asymptomatic and 79 in symptomatic patients \[[@pone.0120181.ref010]\]). These differences were unlikely a consequence of the regular liver surveillance, as patients were referred from centers with different follow-up practices, varying from regular liver function tests and liver ultrasound every 6 months to no surveillance. Regardless, the analysis performed was not influenced by the duration of survival itself, but rather by the influence different factors had on survival. To confirm the reproducibility of our results, the nomogram was validated with very good performance despite the significant differences observed for some prognostic predictors between IOV's and Mayo's patients. We obtained two bi-phasic survival curves, with a steep slope flatting out after about 20 months ([Fig. 1](#pone.0120181.g001){ref-type="fig"}), similar to the curve reported by Rietschel *et al*. \[[@pone.0120181.ref010]\], suggesting as a confirmation of the heterogeneity of this disease. Although the liver was the most prevalent metastatic site, we identified a number of patients who had metastases in other organs. However, the majority of the patients with mUM died as a result of liver progression despite first developing metastatic disease at another site. Therefore, we cannot advise for routine screening of extra-hepatic sites.

Conclusions {#sec013}
===========

In summary, we developed and externally validated a nomogram that predicts survival in patients with mUM. This nomogram may be useful in stratifying patients in future clinical trials and help providers prognosticate.

Supporting Information {#sec014}
======================

###### The effect of individual predictors on log survival time.

A value of zero was used as the reference value for all predicted 95% confidence intervals are shown. "Rug plots" on curves show the density of the predictor.

(TIF)

###### 

Click here for additional data file.

###### Simulation of nomogram use.

Total points for a patient with PS = 0 (0 points), 20% of liver replacement by metastatic disease (11 points), a LDH serum twice the upper normal limit (72 points), and metastases diagnosed 6 months after initial diagnosis of UM (33 points) were tabulated. The sum 116, corresponds to a survival probability of 0.87 at 6 months, 0.68 at 12 months and approximately 0.35 at 24 months.

(TIF)

###### 

Click here for additional data file.

###### Primary melanoma characteristics, impact on survival and results in multivariate analysis.

Primary melanoma characteristics did not have a significant prognostic value in multivariate survival analysis of metastatic patients. 95% CI and *p* refer to the multivariate analysis required to determine the prognostic factors for the model.

(DOC)

###### 

Click here for additional data file.

###### Proportional Hazard confirmation by Schoenfeld residuals.

Proportional Hazard hypothesis is confirmed.

(DOCX)

###### 

Click here for additional data file.
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